Cargando…
Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Cur...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785572/ https://www.ncbi.nlm.nih.gov/pubmed/27081524 http://dx.doi.org/10.1038/hgv.2015.9 |